Background: Ameloblastic carcinoma secondary type is an extremely rare and aggressive odontogenic neoplasm that exhibits histological features of malignancy in primary and metastatic sites. It arises through carcinomatous de-differentiation of a pre-existing ameloblastoma or odontogenic cyst, typically following repeated treatments and recurrences of the benign precursor neoplasm. Identification of an ameloblastic carcinoma, secondary type presenting with histologic features of malignant transformation from an earlier untreated benign lesion remains a rarity. Herein, we report 1 such case.
Case Report: A 66-year-old man was referred for management of a newly diagnosed ameloblastic carcinoma. He underwent radical surgical intervention comprising hemimandibulectomy, supraomohyoid neck dissection, and free-flap reconstruction. Final histologic analysis demonstrated features suggestive of carcinomatous de-differentiation for a consensus diagnosis of ameloblastic carcinoma, secondary type (de-differentiated) intraosseous.
Conclusions: Ameloblastic carcinoma, secondary type represents a rare and challenging histologic diagnosis. Radical surgical resection with adequate hard and soft tissue margins is essential for curative management of localized disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492487 | PMC |
http://dx.doi.org/10.12659/AJCR.893918 | DOI Listing |
J Stomatol Oral Maxillofac Surg
November 2024
Sorbonne Université, Paris, France; Department of Maxillo-Facial Surgery, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France; Sorbonne université, INSERM UMRS 938, Centre de Recherche de Saint Antoine, Team Cancer Biology and Therapeutics, France.
Introduction: The prognosis of metastatic ameloblastoma (METAM), now defined as a benign tumor, and malignant odontogenic tumors (MOT) is poorly studied in the literature. The aim of this study was to determine the prognosis and factors influencing the survival of these patients.
Material And Methods: Using the SEER database, we retrieved clinical data of patients with malignant tumors of dental origin between 1975 and 2020.
Head Neck Pathol
October 2024
Department of Oral and Maxillofacial Pathology, Faculty of Health Sciences, University of Pretoria, Pretoria Oral Health Care Centre, Office 6-11, Corner of Steve Biko and Dr Savage Roads, Pretoria, 0084, South Africa.
Purpose: The current study aimed to investigate the use of surrogate immunohistochemical (IHC) markers of proliferation and stem cells to distinguish ameloblastoma (AB) from ameloblastic carcinoma (AC).
Methods: The study assessed a total of 29 ACs, 6 ABs that transformed into ACs, and a control cohort of 20 ABs. The demographics and clinicopathologic details of the included cases of AC were recorded.
Oral Maxillofac Surg
December 2024
Department of Oral Diagnostic and Surgical Sciences, University of Otago, Dunedin, New Zealand.
F1000Res
July 2024
Department of Dentistry, Oral Health Institute, Hamad Medical Corporation, Doha, Doha, Qatar.
Background: Differentiating between ameloblastoma (AB) and ameloblastic carcinoma (AC) is difficult, especially when AB has atypical cytological characteristics or an uncommon clinical history. This systematic review and meta-analysis aimed to elucidate the differential expression of immunohistochemical markers between AB and AC.
Methods: We conducted a thorough search of PUBMED and SCOPUS according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify cross-sectional studies that compared the expression of immunohistochemical markers in AB and AC.
Ann Afr Med
July 2024
Department of Medical Microbiology and Parasitology, Centre for Human and Zoonotic Virology, College of Medicine, University of Lagos.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!